Research
FORUM TRANSCRIPT

“4+7” Drug Centralised Procurement Policy – Impact on Pharmaceutical Companies – 3 January 2019

  • Multi Asset
  • Healthcare
  • Global
PREMIUM

Specialist

Former Senior Manager at Yangtze River Pharmaceutical Group Beijing Haiyan Pharmaceutical Co Ltd

Agenda

  • Commentary on the latest round of bidding process, winning products and price reduction negotiations
  • Attitudes of winning domestic and foreign companies, impact on their sales and profit, short-term and long-term countermeasures
  • Pharmaceutical companies’ sales strategies, plus impact on the competition between generic and originator drugs

Questions

For access to this and thousands of other Transcripts, request a free trial

Request A Demo